Lincoln Pharmaceuticals Limited — Investor Meet, 23-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Lincoln Pharma reported Q3 FY26 revenue of INR166.32 Cr (up from INR146.55 Cr YoY), EBITDA of INR38.74 Cr, and PAT of INR28.60 Cr. EPS for Q3 was INR14.28, and INR38.07 for 9M. Management targets 12-18% annual growth, aiming for INR1,000 Cr revenue. A new R&D center and Cepha block are operational, with Cepha targeting INR45 Cr this year. Regulated market expansion in Canada sees current business around $4-5 million, expected to grow to $10-15 million. The company seeks inorganic growth opportunities and expects EBITDA margins of 15-18%.